trending Market Intelligence /marketintelligence/en/news-insights/trending/G5bN3C_8eWG6DWnE1Wm1IQ2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Ironwood, Allergan geographically expand license agreement


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Ironwood, Allergan geographically expand license agreement

Ironwood Pharmaceuticals Inc. and Allergan PLC agreed to geographically expand an existing license that provides for the commercialization of Linaclotide for the treatment of irritable bowel syndrome with constipation.

The 2009 agreement allowed Allergan to commercialize the treatment in Europe but is now being amended to include all geographies except China, Japan and the North America.

Allergan is required to make royalty payments on sales of the drug in the additional geographies.

Ironwood is also foregoing its share of profits from the sale of Linaclotide in North America in exchange for receiving royalties on the sale of Canasa and Delzicol in the U.S.

Allergan has engaged Ironwood to promote the drugs for the two-year period ending Feb. 26, 2019.